2026-04-14T07:26:57Zhttps://recercat.cat/oai/requestoai:recercat.cat:10230/560702025-12-18T01:11:50Zcom_2072_6col_2072_452952
Sensitization to isothiazolinones in the Spanish Contact Dermatitis Registry (REIDAC). 2019-2021 epidemiological situation
Hernández Fernández, Carlos Pelayo
Giménez Arnau, Anna Maria
García-Doval, Ignacio
Spain
Benzisothiazolinone
Contact dermatitis
Methylchloroisothiazolinone/methylisothiazolinone
Methylisothiazolinone
Octylisothiazolinone
Patch tests
Standard series
Background: current frequency and risk factors for sensitization to methylisothiazolinone (MI), methylchloroisothiazolinone/methylisothiazolinone (MCI/MI), benzisothiazolinone (BIT) and octylisothiazolinone (OIT) in Spain are not well known. Objectives: to study the frequency of sensitization, risk factors and simultaneous sensitization between the four isothiazolinones. Materials and methods: we analysed all 2019-2021 consecutive patients patch-tested with MI (0.2% aq.), MCI/MI (0.02% aq.), BIT (0.1% pet.) and OIT (0.1% pet) within the Spanish Contact Dermatitis Registry (REIDAC). Results: a total of 2511 patients were analysed. Frequencies of sensitization were: any isothiazolinone 15.7%, MI 6.8%, MCI/MI 4.8%, BIT 3.5% and OIT 0.5%. MI and MCI/MI sensitization was associated with being occupationally active, hand dermatitis, detergents and age over 40. BIT sensitization was associated with leg dermatitis and age over 40. About one in nine MI-positive patients were positive to BIT, whereas one in five BIT-positive patients were positive to MI. Conclusions: sensitization to MI, MCI/MI and BIT is still common in Spain, while sensitization to OIT is rare. Currently, sensitization to MI and MCI/MI seems to be occupationally related. Although its origin is unknown, sensitization to BIT is more frequent in patients aged over 40 years. Simultaneous sensitization between MI and BIT is uncommon.
2023-03-07T08:00:20Z
2023-03-07T08:00:20Z
2022
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License https://creativecommons.org/licenses/by-nc-nd/4.0/, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. © 2022 The Authors. Contact Dermatitis published by John Wiley & Sons Ltd.
http://creativecommons.org/licenses/by-nc-nd/4.0/
info:eu-repo/semantics/openAccess
Wiley